Moe Alsumidaie

http://Moe%20Alsumidaie
Chief Editor
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.

AI Drug Discovery AstraZeneca BIO-Europe Spring 2026 biopharma M&A biopharma strategy biotech funding biotech strategy business development cancer immunotherapy China Biotech CNS Pipeline Strategy competitive intelligence Disease-Modifying Therapy Drug Pricing Strategy eClinical Tech News Eli Lilly Emerging Markets FDA Approval FDA Priority Review HER2 Oncology immuno-oncology immunology licensing deals Lifecycle Management Market Access Medtronic MSS colorectal cancer Novo Nordisk Obesity/GLP-1 Obesity Drug Market Obesity Market Oncology Pipeline Patent Cliff Priority Review Voucher pulmonary hypertension Rare Disease Regeneron respiratory biologics Roche Sanofi series A funding Teva Pharmaceuticals Type 1 Diabetes Type 2 Diabetes venture capital

Pharma Vanguard
  • Articles
  • Conference Coverage
  • Executive Interviews
  • News
  • CliniCast

SUBSCRIBE


  Thank you for Signing Up

Subscribe to The Clinical Trial Vanguard

Please complete this form to create an account, receive email updates and much more.
  Please correct the marked field(s) below.
Contact Email  *
1,true,6,Contact Email,2
First Name *
1,true,1,First Name,2
Last Name *
1,true,1,Last Name,2
Company Size *
  1,true,3,Company Size,2
Company Type *
  1,true,3,Company Type,2
Role Rank *
  1,true,3,Role Rank,2
Function *
  1,true,3,Function,2
*Required Fields
I agree to the  Privacy Policy and  Terms of Use and receive communications from The Clinical Trial Vanguard
Note: It is our responsibility to protect your privacy and we guarantee that your data will be completely confidential.

Latest News

  • Neurocrine Biosciences Names Samir Siddhanti Chief Business Officer 01
    News

    Neurocrine Biosciences Names Samir Siddhanti Chief Business Officer

    July 22, 2026
  • Tempest Therapeutics Partners With Senlang on TPST-4003 CAR-T Trial 02
    News

    Tempest Therapeutics Partners With Senlang on TPST-4003 CAR-T Trial

    July 22, 2026
  • Rectify Pharmaceuticals Names Constantine Chinoporos Executive Chairman 03
    News

    Rectify Pharmaceuticals Names Constantine Chinoporos Executive Chairman

    July 17, 2026
  • Adneuris Grants Cebranopadol Greater China Rights to Zhejiang Conba 04
    News

    Adneuris Grants Cebranopadol Greater China Rights to Zhejiang Conba

    July 15, 2026
  • Avere Therapeutics Merges With NextCure in $320M Financing for Oral IL-23 Drug 05
    News

    Avere Therapeutics Merges With NextCure in $320M Financing for Oral IL-23 Drug

    July 15, 2026
  • FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer's 06
    News

    FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s

    July 14, 2026
Pharma Vanguard
  • ABOUT US
  • PRIVACY POLICY
  • SUBSCRIBE
  • TERMS AND CONDITIONS OF ACCESS AND USE
Copyright © 2026 Pharma Vanguard
  • Articles
  • Conference Coverage
  • Executive Interviews
  • News
  • CliniCast

Start typing and press Enter to search